ВАКЦИНА АБКДС-ИПВ//PRP~T: ОБЗОР 16-ЛЕТНЕГО ОПЫТА КЛИНИЧЕСКОГО ПРИМЕНЕНИЯ
https://doi.org/10.15690/vsp.v11i1.129
Аннотация
Благодаря низкой реактогенности, подтвержденной эффективности и включенным в состав ацеллюлярному (бесклеточному) коклюшному компоненту и инактивированной полиовакцине, многокомпонентные комбинированные вакцины в настоящее время широко используют в национальных программах иммунизации по всему миру. Мы представляем обзор 16-летнего опыта клинического применения комбинированной вакцины Пентаксим (АбКДС-ИПВ//PRP~T; Санофи Пастер, Франция), содержащей бесклеточный коклюшный компонент, дифтерийный анатоксин, столбнячный анатоксин, инактивированную полиовакцину и очищенный капсульный полисахарид (PRP) гемофильной палочки типа b (Haemophilus influenzae type b, Hib), конъюгированный со столбнячным протеином (Т). Исследования продемонстрировали высокую иммуногенность первичной вакцинации Пентаксимом независимо от этнических характеристик популяции и схемы введения. Ревакцинация на втором году жизни также приводила к выраженному иммунному ответу на каждый из антигенов. Кроме того, результаты 10-летнего национального исследования в Швеции продемонстрировали эффективность исследуемой вакцины в контроле заболеваемости коклюшем. Как и другие комбинированные вакцины, содержащие бесклеточный коклюшный компонент, вакцина хорошо переносится, при этом ее характеристики безопасности при первичной вакцинации и ревакцинации лучше, чем у комбинированных вакцин, содержащих цельноклеточный коклюшный компонент.
Об авторах
Stanley А. Plotkin
Компания Ваксконсалт (Vaxconsult), Пенсильвания
Соединённые Штаты Америки
Соединённые Штаты Америки
Стенли Плоткин, Почетный профессор Университета Пенсильвании, США
Адрес: Global Medical Affairs, Sanofi Pasteur, 2 Avenue Pont Pasteur, 69367 Lyon,тел.: +33 437 377 258, fax: +33 437 377, e-mail: 171esteban.ortiz@sanofipasteur.comJohannes Liese
Детский университетский госпиталь, Вюрцбург
Германия
Германия
Shabir А. Madhi
Университет Витватерсранда, Йоханнесбург
Южно-Африканская Республика
Южно-Африканская Республика
Esteban Ortiz
Санофи Пастер, Лион
Франция
Франция
Список литературы
1. International Bank for Reconstruction and Development. World Development Report 1993: Investing in Health http://files.dcp2. org/pdf/WorldDevelopmentReport1993.
2. Chandran A., Watt J. P., Santosham M. Haemophilus influenz ae vaccines. In: Vaccines. 5th edition. Plotkin S. A., Orenstein W., Offit P. A. (Eds). USA, Saunders Co., PA, 2008. — Р. 157–175.
3. Edwards K., Decker M. Pertussis vaccines. In: Vaccines. 5th edition. Plotkin S. Orenstein W., Offit P. A. (Eds). USA, Saunders Co., PA, 2008. — Р. 467–517.
4. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st Century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates // Clin. Microbiol. Rev. — 2000; 13 (2): 302–317.
5. Vitek C. R., Wharton M. Diptheria toxoid. In: Vaccines. 5th edition. Plotkin S. A., Orenstein W., Offit P. A. (Eds). USA, Saunders Co., PA, 2008. — Р. 139–155.
6. Wassilak S. G., Roper M. H., Kretsinger K., Orenstein W. A. Tetanus toxoid. In: Vaccines. 5th edition. Plotkin S. A., Orenstein W., Offit P. A. (Eds). USA, Saunders Co., PA, 2008. — Р. 139–155.
7. World Health Organization. Global Immunization Vision and Strategy www.who.int/vaccines-documents/DocsPDF05/GIVS_Final_EN.pdf
8. Edwards K. M., Decker M. D. Combination vaccines: hopes and challenges // Pediatr. Infect. Dis. J. — 1994; 13 (5): 805–839.
9. Pichichero M. E. New combination vaccines // Pediatr. Clin. North. Am. — 2000; 47 (2): 407–426.
10. Obaro S. K., Palmer A. Vaccines for children: policies, politics and poverty // Vaccine. — 2003; 21 (13–14): 1423–1431.
11. Andre F. E., Booy R., Bock H. L. et al. Vaccination greatly reduces disease, disability, death and inequity worldwide // Bull. World Health Organ. — 2008; 86 (2): 140–146.
12. Aristegui J., Usonis V., Coovadia H. et al. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine // Int. J. Infect. Dis. — 2003; 7 (2): 143–151.
13. Decker M. D. Principles of pediatric combination vaccines and practical issues related to use in clinical practice // Pediatr. Infect. Dis. J. — 2001; 20 (11 Suppl.): S10–S18.
14. Decker M., Bogaerts H., Edwards K. Combination vaccines. In: Vaccines. 5th edition. Plotkin S. A., Orenstein W., Offit P. A. (Eds). USA, Saunders Co., PA, 2008. — Р. 1069–1101.
15. Watt J. P., Wolfson L. J., O’Brien K. L. et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates // Lancet. — 2009; 374 (9693): 903–911.
16. World Health Organization. Diphtheria position paper // Wkly Epidemiol. Rec. — 2006; 81 (3): 24–32.
17. World Health Organization. Tetanus position paper // Wkly Epidemiol. Rec. — 2010; 81 (20): 198–208.
18. World Health Organization. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation // Wkly Epidemiol. Rec. — 2006; 81 (15): 137–144.
19. Global Polio Eradication Initiative. Wild poliovirus weekly update www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx
20. Centers for Disease Control and Prevention. Recommended childhood immunization schedule // MMWR. — 2001; 50 (1): 1–3.
21. Centers for Disease Control and Prevention. Update on vaccine-de rived polioviruses — worldwide // MMWR. — 2007; 56 (38): 996–1001.
22. Heymann D. L., Sutter R. W., Aylward R. B. A global call for new polio vaccines // Nature. — 2005; 434 (7034): 699–700.
23. Kew O. M., Sutter R. W., de Gourville E. M. et al. Vaccinederived polioviruses and the endgame strategy for global polio eradication // Annu. Rev. Microbiol. — 2005; 59: 587–635.
24. World Health Organization. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries // Wkly Epidemiol. Rec. — 2003; 78 (28): 241–252.
25. World Health Organization. Vaccine-derived polioviruses — update // Wkly Epidemiol. Rec. — 2006; 81 (42): 398–404.
26. World Health Organization. Global polio eradication initiative strategic plan 2004–2008 www.polioeradication.org/content/publications/2004stratplan.pdf
27. Vashishtha V. M., Kalra A., John T. J. et al. Recommendations of 2nd National Consultative Meeting of Indian Academy of Pediatrics (IAP) on polio eradication and improvement of routine immunization // Indian Pediatr. — 2008; 45 (5): 367–378.
28. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices // MMWR. — 2000; 49: 1–22.
29. Bonnet M. C., Dutta A. World wide experience with inactivated poliovirus vaccine // Vaccine. — 2008; 26 (39): 4978–4983.
30. Decker M. D., Edwards K. M., Steinhoff M. C. et al. Comparison of 13 acellular pertussis vaccines: adverse reactions // Pediatrics. — 1995; 96 (3 Pt 2): 557–566.
31. Pichichero M. E., Deloria M. A., Rennels M. B. et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15-to 20-month-old children // Pediatrics. — 1997; 100 (5): 772–788.
32. Beutels P., Bonanni P., Tormans G. et al. An economic evaluation of universal pertussis vaccination in Italy // Vaccine. — 1999; 17 (19): 2400–2409.
33. Ekwueme D. U., Strebel P. M., Hadler S. C. et al. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997 // Arch. Pediatr. Adolesc. Med. — 2000; 154 (8): 797–803.
34. Tormans G., Van Doorslaer E., Van Damme P., Clara R., Schmitt H. J. Economic evaluation of pertussis prevention by wholecell and acellular vaccine in Germany // Eur. J. Pediatr. — 1998; 157 (5): 395–401.
35. Thisyakorn U., Montellano M., Ortiz E., Lane A. A review of hepatitis B vaccine administration schedules in infants. Presented at: 5th Asian Congress of Pediatric Infectious Diseases. Taipei, Taiwan, 2010.
36. World Health Organization. United Nations pre-qualified vaccines www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html
37. Capeding M. R., Cadorna-Carlos J., Book-Montellano M., Ortiz E. Immunogenicity and safety of a DTaP–IPV // PRPT combination vaccine given with hepatitis B vaccine: a randomized open-label trial. Bull // World Health Organ. — 2008; 86 (6): 443–451.
38. Dutta A. K., Verghese V. P., Pemde H. K. et al. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine // Indian Pediatr. — 2009; 46 (11): 975–982.
39. Madhi S. A., Cutland C., Jones S., Ortiz E. Post-primary vaccination antibody persistence and immunogenicity/safety of a DTaP– IPV // PRPT booster vaccine in South African infants aged 18 to 19 months/Programs and Abstracts of the 26th International Pediatric Association Congress of Pediatrics. Johannesburg, South Africa, 2010.
40. Madhi S. A., Cutland C., Jones S., Ortiz E. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 months of age in infants in South Africa // S. Afr. Med. J. — 2011; 101: 126–131.
41. Kanra G., Silier T., Yurdakok K. et al. Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP–IPV // PRP–T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life // Vaccine. — 1999; 18 (9–10): 947–954.
42. Li R. C., Li F. X., Li Y. P. et al. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China // Vaccine. — 2011; 29 (10): 1913–1920.
43. Langue J., David T., Roussel F. et al. Safety and immunogenicity of DTaP–IPV and Act-Hib vaccines administered either combined or separately to infants at 2, 3, and 4 months of age / Programs and Abstracts of the 15th Annual Meeting of the European Society for Paediatric Infectious Diseases. Paris, France, 1997.
44. Mallet E., Hoffenbach A., Salomon H. et al. Primary immunization with combined, acellular DTaP–IPV–Act-HIB vaccine given at 2–3–4 or 2–4–6 months of age/Programs and Abstracts of the 14th European Societies for Paediatric Infectious Diseases. Elisnore, Denmark, 1996.
45. Reinert P., Boucher J., Pines E. et al. Primary or booster immunization with DTaP–IPV vaccine administered either in combination or in association with Haemophilus influenzae type b vaccine (Act- Hib): a large-scale safety study / Programs and Abstracts of the 15th Annual Meeting of the European Society for Paediatric Infectious Diseases. Paris, France,1997.
46. Lagos R., Kotloff K., Hoffenbach A. et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants // Pediatr. Infect. Dis. J. — 1998; 17 (4): 294–304.
47. Mallet E., Fabre P., Pines E. et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants // Pediatr. Infect. Dis. J. — 2000; 19 (12): 1119–1127.
48. Carlsson R. M., Claesson B. A., Selstam U. et al. Safety and immunogenicity of a combined diphtheria–tetanus–acellular pertussis–inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2–4–6–13 or 3–5–12 months of age // Pediatr. Infect. Dis. J. — 1998; 17 (11): 1026–1033.
49. Carlsson R. M., Claesson B. A., Fagerlund E. et al. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy // Pediatr. Infect. Dis. J. — 2002; 21 (6): 535–541.
50. Thisyakorn U., Pancharoen C., Chuenkitmongkol S., Ortiz E. Immunogenicity and safety of a DTaP–IPV // PRP–T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine // Southeast Asian J. Trop. Med. Public Health. — 2009; 40 (2): 282–294.
51. Thisyakorn U., Chotpitayasunondh T., Pancharoen C. et al. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand // Southeast Asian J. Trop. Med. Public Health. — 2010; 41 (2): 450–462.
52. Englund J. A., Decker M. D., Edwards K. M. et al. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study // Pediatrics. — 1994; 93 (1): 37–43.
53. World Health Organization. Pertussis position paper // Wkly Epidemiol. Rec. — 2010; 85 (40): 385–400.
54. Le Saux N., Barrowman N. J., Moore D. L. et al. Decrease in hospital admissions for febrile seizures and reports of hypotonichyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT // Pediatrics. — 2003; 112 (5): 348.
55. Collins C. L., Salt P., Mc Carthy N. et al. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children // Vaccine. — 2004; 22 (31–32): 4262–4269.
56. Langue J., Matisse N., Pacoret P. et al. Persistence of antibodies at 5–6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5–6 years of age // Vaccine. — 2004; 22 (11–12): 1406–1414.
57. Mallet E., Matisse N., Mathieu N. et al. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5–6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster // Vaccine. — 2004; 22 (11–12): 1415–1422.
58. Plotkin S. A. Correlates of protection induced by vaccination // Clin. Vaccine Immunol. — 2010; 17 (7): 1055–1065.
59. Carlsson R. M., Trollfors B. Control of pertussis — lessons learnt from a 10-year surveillance programme in Sweden // Vaccine. — 2009; 27 (42): 5709–5718.
60. Okada K., Ohashi Y., Matsuo F. et al. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study // Epidemiol. Infect. — 2009; 137 (1): 124–130.
61. World Health Organization. Validation of neonatal tetanus elimination in selected states — India // Wkly Epidemiol. Rec. — 2008; 83 (21): 185–192.
62. Vidor E., Plotkin S. A. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations // Hum. Vaccine. — 2008; 4 (5): 328–340.
63. Dutta A., Verghese V. P., Pemde H. K. et al. Post-primary vaccination antibody persistence and immunogenicity and safety of a DTaP–IPV // PRPT booster vaccination at 18 to 19 months of age in Indian infants / Programs and Abstracts of the 3rd Asian Pacific Congress of Pediatrics. Shanghai, China, 2009.
64. Li R. C., Li F. X., Li Y. P. et al. Antibody persistence at 18–20 months of age following primary vaccination of healthy infants with a combined DTaP–IPV // PRPT vaccine compared to separate vaccines (DTaP, PRPT and IPV) and immunogenicity and safety of booster vaccination in the Peoples’ Republic of China/Programs and Abstracts of the 5th Asian Congress of Pediatric Infectious Diseases. Taipei, Taiwan, 2010.
65. Gustafsson L., Hessel L., Storsaeter J., Olin P. Long-term followup of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age // Pediatrics. — 2006; 118 (3): 978–984.
66. Thisyakorn U., Chotpitayasunondh T., Pancharoen C. et al. Postprimary vaccination antibody persistence and immunogenicity / safety of a DTaPIPV // PRPT booster at 18 to 19 months of age in Thai infants/Programs and Abstracts of the 6th Congress of the World Society for Pediatric Infectious Diseases. Buenos Aires, Argentina, 2009.
67. Zhang L., Prietsch S. O. M., Axelsson I., Halperin S. Acellular vaccines for preventing whooping cough in children // Cochrane Database Syst. Rev. — 2011; 1: CD001478.
68. Jefferson T., Rudin M., Di Pietrantonj C. Systematic review of the effects of pertussis vaccines in children // Vaccine. — 2003; 21 (17–18): 2003–2014.
69. Desauziers E., Hessel L., Decker M. D. et al. Systematic review of the effects of pertussis vaccines in children // Vaccine. — 2004; 22 (21–22): 2681–2684.
70. Simondon F. Systematic review of the effects of pertussis vaccines in children // Vaccine. — 2004; 22 (23–24): 2965.
71. Gustafsson L., Hallander H. O., Olin P. et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine // N. Engl. J. Med. — 1996; 334 (6): 349–355.
72. Bonmarin I., Levy-Bruhl D., Baron S. et al. Pertussis surveillance in French hospitals: results from a 10 year period // Euro Surveill. — 2007; 12 (1): 6.
73. Olin P., Hallander H. O. Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden // Euro Surveill. — 1999; 4 (12): 128–129.
74. Rendi-Wagner P., Paulke-Korinek M., Stanek G. et al. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria // Pediatr. Infect. Dis. J. — 2007; 26 (9): 806–810.
75. Liese J. G., Stojanov S., Peters A. Duration of efficacy after primary immunisation with Biken acellular pertussis vaccine (Tripedia)/Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 2003.
76. Liese J. G., Meschievitz C. K., Harzer E. et al. Efficacy of a twocomponent acellular pertussis vaccine in infants // Pediatr. Infect. Dis. J. — 1997; 16 (11): 1038–1044.
77. Swedish Institute for Infectious Disease Control. Pertussis surveillance in Sweden with enhanced follow-up of cohorts immu - nized with acellular pertussis vaccines 2009. Appendix 2 to Elevenyear Report www.smittskyddsinstitutet.se/upload/Publikationer/ 11-y-report-app202-SPMSD.pdf
78. Rendi-Wagner P., Kundi M., Mikolasek A. et al. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine // Vaccine. — 2006; 24 (33–34): 5960–5965.
79. Hviid A., Stellfeld M., Andersen P. H. et al. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark // Vaccine. — 2004; 22 (27–28): 3530–3534.
80. Hviid A. Post-licensure epidemiology of childhood vaccination: the Danish experience // Expert Rev Vaccines. — 2006; 5 (5) 6 641–649.
81. Watanabe M., Nagai M. Acellular pertussis vaccines in Japan: past, present and future // Expert Rev. Vaccines. 2005; 4 (2): 173–184.
82. Liese J. G., Stojanov S., Froeschle J. et al. Long term efficacy of Biken acellular pertussis vaccine (Tripedia) / Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Toronto, Canada, 2000.
83. Bisgard K. M., Rhodes P., Connelly B. L. et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998–2001 // Pediatrics. — 2005; 116 (2): e285–e294.
84. Eskola J., Ward J., Dagan R. et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria–tetanus– pertussis containing acellular pertussis // Lancet. — 1999; 354 (9195): 2063–2068.
85. Hoppenbrouwers K., Kanra G., Roelants M. et al. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b–tetanus toxoid conjugate (PRP–T) and diphtheria–tetanus– acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey // Vaccine. — 1999; 17 (7–8): 875–886. 86. Greenberg D. P., Doemland M., Bettinger J. A. et al. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae type b pediatric combination vaccine and an adolescent–adult tetanus– diphtheria–acellular pertussis vaccine: implications for disease prevention in the United States // Pediatr. Infect. Dis. J. — 2009; 28 (6): 521–528.
86. Kalies H., Verstraeten T., Grote V. et al. Four and one-halfyear follow-up of the effectiveness of diphtheria–tetanus toxoids– acellular pertussis/Haemophilus influenzae type b and diphtheria– tetanus toxoids–acellular pertussis–inactivated poliovirus / H. influenzae type b combination vaccines in Germany // Pediatr. Infect. Dis. J. — 2004; 23 (10): 944–950.
87. Schmitt H. J., von Kries R., Hassenpflug B. et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria– tetanus toxoids–acellular pertussis (–inactivated poliovirus) / H. influenzae type b combination vaccines // Pediatr. Infect. Dis. J. — 2001; 20 (8): 767–774.
88. Cruces R. P., Donoso F.A., Camacho A. J. et al. Invasive infections caused by Haemophilus influenzae type b after the institution of the conjugated vaccine on the expanded programme on immunization // Chile. Rev. Chilena. Infectol. — 2006; 23 (1): 50–54.
89. Kelly D. F., Moxon E. R., Pollard A. J. Haemophilus influenza type b conjugate vaccines // Immunology. — 2004; 113 (2): 163–174.
90. Cameron C., Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules // Euro Surveill. — 2006; 11 (3): E060302.
91. Ladhani S., Heath P. T., Slack M. P. et al. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes // Clin. Microbiol. Infect. — 2010; 16 (7): 948–954.
92. World Health Organization. Haemophilus influenzae type b conjugated vaccines — WHO position paper // Wkly Epidemiol. Rec. — 2006; 81 (47): 445–452.
93. Garpenholt O., Hugosson S., Fredlund H. et al. Invasive disease due to Haemophilus influenzae type b during the first six years of general vaccination of Swedish children // Acta Paediatr. — 2000; 89 (4): 471–474.
94. Edmunds W. J., Brisson M., Melegaro A., Gay N. J. The potential cost–effectiveness of acellular pertussis booster vaccination in England and Wales // Vaccine. — 2002; 20 (9–10): 1316–1330.
95. Iskedjian M., De Serres G., Einarson T. R. et al. Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis // Vaccine. — 2010; 28 (3): 714–723.
96. Kosalaraska P., Thisyakorn U., Benjaponpitak S. et al. Immunogenicity and safety study of a new DTaP–IPV–Hep B–PRP–T combined vaccine compared to a licensed DTaP–IPV–Hep B // PRP–T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, 6 months of age in Thai infants // Int. J. Infect. Dis. — 2011; 15: e249–e256.
97. Lee S. Y., Hwang H. S., Kim J. H. et al. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP–IPV) compared to separate administration of standalone DTaP and IPV vaccines: A randomized, controlled study in infants in the Republic of Korea // Vaccine. — 2011; 29 (8): 1551–1557.
Рецензия
Для цитирования:
Plotkin S.А., Liese J., Madhi S.А., Ortiz E. ВАКЦИНА АБКДС-ИПВ//PRP~T: ОБЗОР 16-ЛЕТНЕГО ОПЫТА КЛИНИЧЕСКОГО ПРИМЕНЕНИЯ. Вопросы современной педиатрии. 2012;11(1):18-36. https://doi.org/10.15690/vsp.v11i1.129
For citation:
Plotkin S.A., Liese J., Madhi S., Ortiz E. A DTAP–IPV//PRP~T VACCINE: A REVIEW OF 16 YEARS’ CLINICAL EXPERIENCE. Current Pediatrics. 2012;11(1):18-36. (In Russ.) https://doi.org/10.15690/vsp.v11i1.129
Просмотров: 1731
Послать статью по эл. почте 
